Beat AML Master Trial: A Groundbreaking Clinical Trial for Acute Myeloid Leukemia Patients

Milestones in Acute Myeloid Leukemia Treatment

- **Cytarabine/Daunorubicin**: Development of 7+3 protocol for acute myeloid leukemia (AML) patients. – More than 40 years later this combination still remains the standard treatment combination for AML patients. – 1973

- **Bone Marrow Transplant**: bone marrow transplant for AML first employed; still the only potentially curative therapy, but comes with high risk. – 1977

- **Mylotarg**: FDA approval of Mylotarg (gentuzumab) - is a drug-linked monoclonal antibody (an antibody-drug conjugate) that was used to treat AML patients from 2000 to 2010. It was withdrawn from market in June 2010 when a clinical trial showed the drug increased patient death and added no benefit over conventional cancer therapies. – 1977

- **Celator**: LLS enters partnership with Celator Pharmaceuticals to fund a Phase 2 clinical trial for CPX-351, an innovative reformulation of cytarabine and daunorubicin. – 2009

- **Celator**: LLS enters second agreement with Celator to fund a Phase III trial for newly diagnosed secondary AML patients. – 2012

- **Beat AML**: LLS and Brian Druker, M.D., OHSU Knight Cancer Institute, launch Beat AML, a major collaboration to use advanced genomic analysis to identify genetic mutations of AML and test different drugs to develop precision medicine approach to treat AML patients. – 2013

- **CAR-T**: Helen Heslop, MD., Baylor, awarded grant to lead an LLS Specialized Center of Research grant in adoptive T-cell based immunotherapies for several types of blood cancers, including AML. – 2013-2018

For more information contact Andrea Greif, LLS senior director of communications, andrea.greif@lls.org or (914) 821-8958.
Celator: Positive Phase III results from CPX-351 announced. – March 2016

Beat AML Master Trial: LLS collaborates with OHSU Knight Cancer Institute, The Ohio State University Comprehensive Cancer Center, Memorial Sloane Kettering Cancer Center, Dana-Farber Cancer Center and Massachusetts General Hospital Cancer Center, and multiple pharmaceutical companies, FDA, clinical research organization, genomic provider, and patients to launch groundbreaking multi-site, multi arm Master Trial in AML – 2016 and beyond